Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

51.84
-5.1100-8.97%
Post-market: 51.850.0100+0.02%19:59 EDT
Volume:2.30M
Turnover:120.88M
Market Cap:4.98B
PE:-8.42
High:55.99
Open:55.99
Low:51.15
Close:56.95
52wk High:78.48
52wk Low:39.59
Shares:95.99M
Float Shares:90.53M
Volume Ratio:1.23
T/O Rate:2.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.1542
EPS(LYR):-6.4700
ROE:-31.21%
ROA:-14.06%
PB:2.74
PE(LYR):-8.01

Loading ...

Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next

Simply Wall St.
·
Yesterday

Shareholders Approve New Incentive Plan and Governance Measures

TIPRANKS
·
Jun 05

CRISPR Therapeutics shareholders approve 2026 stock option and incentive plan at annual meeting

Reuters
·
Jun 05

Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Jun 04

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift

Simply Wall St.
·
May 29

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 28

Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial

TIPRANKS
·
May 23

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)

TIPRANKS
·
May 14

A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest

Simply Wall St.
·
May 12

Vertex Pharmaceuticals announces Casgevy reimbursement agreement

TIPRANKS
·
May 07

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 06

Editas Medicine Announces First Quarter 2026 Results and Business Updates

GlobeNewswire
·
May 05

CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83

TIPRANKS
·
May 05

CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated

TIPRANKS
·
May 05

CRISPR Therapeutics Ag : Bofa Global Research Cuts Price Objective to $83.00 From $86.00

THOMSON REUTERS
·
May 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeneDx Holdings (WGS) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 05

Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 05

CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Switzerland's CRISPR Therapeutics Q1 net loss narrows

Reuters
·
May 05